Anti-collagen type v: a marker of early systemic sclerosis?
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Citação
ADVANCES IN RHEUMATOLOGY, v.59, article ID 19, 5p, 2019
Resumo
Objective: To evaluate the frequency of anti-collagen type V in humans with early systemic sclerosis (SSc) compared to defined SSc patients and healthy controls, since collagen type V was shown to be overexpressed in early SSc patients' skin and there is no data concerning the presence of this antibody in early stages of human SSc. Experimental studies showed that animal models immunized with collagen type V developed a disease similar to human systemic sclerosis (SSc), with antibodies production, mainly in early stages post-immunization. Methods: Eighty-one female SSc patients were included and divided into two groups: early-SSc (18 patients-EULAR Preliminary Criteria) and defined-SSc (63 patients-ACR Criteria 1980). The control group consisted of 19 healthy women age-matched to Early-SSc group. Anti-collagen type V was performed by ELISA. Data was analyzed by appropriate tests. Results: The prevalence of anti-collagen type V in early-SSc, defined-SSc and control groups was respectively 33, 17 and 5% (p = 0.07). SSc patients with anti-collagen type V had shorter disease duration compared to those without this antibody (8.8 +/- 5.1 vs. 14.7 +/- 8.9, p = 0.006). Likewise, early-SSc patients with anti-collagen V also had a shorter disease duration than patients negative for this antibody (4.6 +/- 2.2 vs. 9.7 +/- 5.2, p = 0.04). No association with clinical subsets or scleroderma antibodies specificities was observed (p > 0.05). Conclusion: The production of anti-collagen type V in SSc seems to be an early event independent of other antibodies specificities. Further studies are necessary to determine if the underlying mechanism for this chronology involves a primary immune response to abnormal expression of collagen type V.
Palavras-chave
Collagen type V, Systemic sclerosis, Scleroderma, Antibodies, Biomarker, Diagnostic test
Referências
- [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581
- Avouac J, 2011, ANN RHEUM DIS, V70, P476, DOI 10.1136/ard.2010.136929
- Bezerra MC, 2006, ARCH DERMATOL RES, V298, P51, DOI 10.1007/s00403-006-0645-5
- Burlingham WJ, 2007, J CLIN INVEST, V117, P3498, DOI 10.1172/JC128031
- Callado MRM, 2007, IMMUNOLOGY, V122, P38, DOI 10.1111/j.1365-2567.2007.02610.x
- Dart ML, 2010, CIRC RES, V107, P1106, DOI 10.1161/CIRCRESAHA.110.221069
- de Oliveira CC, 2009, CLINICS, V64, P577, DOI 10.1590/S1807-59322009000600014
- Dellavance Alessandra, 2009, Rev. Bras. Reumatol., V49, P89, DOI 10.1590/S0482-50042009000200002
- Fessler LI, 1987, STRUCTURE FUNCTION C, P81
- Furst DE, 1998, J RHEUMATOL, V25, P84
- Martin P, 2012, AUTOIMMUN REV, V11, P827, DOI 10.1016/j.autrev.2012.02.017
- RIENTE L, 1995, CLIN EXP IMMUNOL, V102, P354
- Teodoro WR, 2004, PATHOL RES PRACT, V200, P681, DOI 10.1016/j.prp.2004.05.007
- Tiriveedhi V, 2012, CLIN EXP IMMUNOL, V167, P158, DOI 10.1111/j.1365-2249.2011.04486.x